Autobahn Therapeutics is a San Diego clinical-stage biotech building small-molecule medicines that reach the brain on purpose. Using a brain-targeting chemistry and prodrug platform, the company tunes where a drug goes - central versus peripheral - to unlock validated CNS biology that has been hard to drug safely. Its lead program, elunetirom (ABX-002), is an oral, once-daily, brain-penetrant CNS thyroid hormone receptor agonist in Phase 2 trials for major depressive disorder and bipolar depression, backed by more than $200 million in venture funding and a 2026 FDA Fast Track designation.
Kim Seth, Ph.D., is the founding President & CEO of Nilo Therapeutics, a New York biotech that launched in October 2025 with a $101 million Series A to build medicines that talk to the immune system through the brain. A Harvard-trained neurobiologist turned dealmaker, he spent 25-plus years moving between Goldman Sachs, Pfizer, and Repare Therapeutics - where he helped take a precision-oncology startup from pre-Series A to IPO - before betting his own career on the strange idea that the vagus nerve might be the most underused drug target in autoimmune disease.